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Abstract
Major depressive disorder is the main cause of disability worldwide with imperfect treatment options. However, novel
therapeutic approaches are currently discussed, from augmentation strategies to novel treatments targeting the
immune system or the microbiome-gut-brain axis. Therefore, we examined the potential beneﬁcial effects of
minocycline, a tetracycline antibiotic with pleiotropic, immunomodulatory action, alone or as augmentation of
escitalopram on behavior, prefrontal microglial density, and the gut microbiome in rats selectively bred for high
anxiety-like behavior (HAB). We show that concomitant with their high innate anxiety and depression, HABs have
lower microglial numbers in the infralimbic and prelimbic prefrontal cortex and an altered gut microbiota composition
compared with controls. Three weeks of minocycline treatment alleviated the depressive-like phenotype, further
reduced microglial density, exclusively in male HAB rats, and reduced plasma concentrations of pro-inﬂammatory
cytokines. However, coadministration of escitalopram, which had no effect alone, prevented these minocycline-
induced effects. Moreover, minocycline led to a robust shift in cecal microbial composition in both HABs and rats non-
selected for anxiety-like behavior. Minocycline markedly increased relative abundance of Lachnospiraceae and
Clostridiales Family XIII, families known for their butyrate production, with a corresponding increase and positive
correlation in plasma 3-OH-butyrate levels in a trait-dependent manner. Thus, our data suggest that the antidepressant
effect of minocycline is sex- and trait-dependent, associated with a reduced microglial number in the prefrontal cortex,
and with changes in microbial composition and their metabolites. These results further support the microbiome-
gut–brain axis as potential target in the treatment of depression.
Introduction
According to the World Health Organization, depres-
sion has become the leading cause of disability worldwide
affecting approximately 300 million people with a lifetime
prevalence of 10.7% in men and 18.1% in women in the
US1. Numerous treatment options for major depressive
disorder (MDD) are available such as the frequently pre-
scribed and highly efﬁcacious selective serotonin reuptake
inhibitor (SSRI) escitalopram2,3. However, antidepressants
display a therapeutic lag of 2–4 weeks, and only 70% of
patients respond sufﬁciently4. To achieve therapies with
faster onset, two major approaches can be utilized, i.e.
optimization of existing options or the discovery of agents
with novel mechanisms of action. Treatment regimens
move towards augmentation strategies, a combination of
conventional antidepressants with non-antidepressant
substances to increase efﬁcacy and overcome treatment
resistance5. Regarding novel targets, central inﬂammation
and the microbiome-gut–brain axis are two areas
receiving growing traction6,7.
Thus, dysregulation in microglia, the immune system of
the brain, as well as the gut microbiome have been
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associated with MDD8–11. A signiﬁcant inﬂuence of
microbiota on microglia activation and maturation,
potentially via bacteria-produced short-chain fatty acids
like butyrate, has been reported12,13. This points towards a
complex role of microbiota and microglia in anxiety and
depression, suggesting a subtle interplay between beha-
vior, microglia and microbiota. In light of this, one
attractive treatment option is the pleiotropic broad-
spectrum tetracycline antibiotic minocycline, with neu-
roprotective and anti-inﬂammatory properties, e.g. inhi-
biting microglial activation14–17, which also affects gut
microbiota18. Recent clinical studies have shown that
minocycline can augment the clinical efﬁcacy of anti-
depressants19–21, an effect that was proposed to be
dependent on the presence of an inﬂammatory state22.
These ﬁndings are supported by several rodent studies
showing that minocycline promotes active stress cop-
ing23,24 and reverses inﬂammation-induced25,26 as well as
stress-induced depressive-like behavior27,28. However,
substantial evidence is required from appropriate animal
models regarding behavioral effects of minocycline and
particularly relating to its mechanism(s) of action.
One of the most heuristic approaches to develop
appropriate animal models is via selective breeding for a
particular trait29. This approach gave rise to Wistar rats
with extremely high anxiety-related behavior (HAB) based
on their performance on the elevated plus-maze (EPM), a
phenotype repeatedly conﬁrmed independent of sex.
Moreover, HAB rats consistently show similar char-
acteristics as observed in MDD patients including passive
stress-coping, altered serotonin and neuropeptide signal-
ing in the brain and, consequently, dysregulated responses
of the hypothalamic–pituitary–adrenal (HPA) axis30–33.
The highly anxious and depressive-like phenotype of male
HAB rats has been successfully reversed by chronic cita-
lopram or paroxetine treatment34,35. However, this
required an 8-week treatment regimen, suggesting HAB
rats as an animal model for comorbid anxiety and
depression, as well as treatment-resistant depression.
Amelioration of these behavioral deﬁcits in female HAB
rats remains to be studied, an approach urgently needed
considering the more frequent diagnosis of MDD in
women30.
Changes in several cortical and limbic structures like
the hippocampus, amygdala and especially the prefrontal
cortex (PFC) are documented in the pathophysiology of
depression36–40. Fittingly, intra-PFC citalopram micro-
infusion acted as an antidepressant41, whereas glial loss in
this region facilitated depressive-like behavior42. More-
over, stress- or inﬂammation-induced depressive-like
behavior paralleled by PFC microglial activation was
prevented by minocycline treatment25,27,43. Importantly,
acute inactivation of the infralimbic cortex in HAB rats
attenuated depressive-like behavior, corresponding to the
behavioral consequences of deep brain stimulation of
Brodmann Area 25 in MDD patients39,44, indicating the
translational relevance of this animal model and the
importance of this region.
Based on these prerequisites, we assessed the effects of
chronic minocycline treatment on anxiety- and
depressive-like behavior in rats in dependence on trait
anxiety levels in both sexes. For translational comparison
with clinical studies using minocycline as an add-on
treatment, the standard SSRI escitalopram and the aug-
mentation of minocycline with escitalopram were inclu-
ded. In order to approach potential mechanisms
underlying the differential treatment effects, we further
examined microglia density in the PFC, peripheral
immune function comprising pro-inﬂammatory cyto-
kines, and alterations in gut microbiota. Male and female
rats non-selected for anxiety (NAB) were included to
determine a trait-dependency of treatment.
Methods and materials
Animals
Male and female NAB rats were either purchased from
Charles River (Wistar rats; Sulzfeld, Germany) or, like all
male and female HAB rats, bred at the University of
Regensburg. HAB rats showing <10% of time spent on
the open arms of an EPM at the age of 9 weeks were
selected45. All rats were maintained on a 12-h light–dark
cycle in a temperature controlled colony (22–24 °C; 55±5%
Humidity) with free access to food and tap water (vehicle)
or drug solution (minocycline and/or escitalopram, see
experimental design) under facility-speciﬁc husbandry
conditions according to the respective EU regulations
(2010/63/EU). All experimental procedures were approved
by the Committee on Animal Health and Care of the local
government, and performed according to the Guide for
the Care and Use of Laboratory Animals of the Govern-
ment of Oberpfalz and Unterfranken, the ARRIVE
guidelines46, and recommendations from the NIH.
Experimental design
At the age of 11–12 weeks, rats were group-housed in
cages of 3–4 rats according to their experimental group
(i.e. sex and trait) and randomly assigned to the treatment.
Body weight and water consumption were monitored
daily to calculate the respective concentrations needed for
oral drug administration via drinking water and to pre-
pare fresh solutions daily. In the ﬁrst set of experiments,
40 mg/kg/day minocycline43, 10 mg/kg/day escitalo-
pram47, or a combination of both substances with the
same concentrations, while in the second set, 80 mg/kg/
day minocycline alone, all dissolved in tap water, was
applied for 22 days. The treatment duration was chosen
based on the fact that antidepressant treatment generally
needs 2–3 weeks for the onset of therapeutic efﬁcacy48
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and on a previous study showing an antidepressant effect
of minocycline already after 7 days28. Minocycline
hydrochloride and escitalopram oxalate were kindly pro-
vided by the Charité Berlin and Lundbeck A/S (Copen-
hagen, Denmark), respectively.
Rats were tested in the social preference test (SPT; day
15), in the light–dark box (LDB; day 17) and on the EPM
(day 19), as well as in the forced swim test (FST; day 22;
Fig. 1a). Behavioral tests were conducted between 0900
and 1200 except for the SPT (1900 to 2200) and behavioral
analysis was conducted by an observer blind to the trait
and treatment. Vaginal smears were taken after the EPM
and FST to control for estrous cycle. Immediately after the
FST, all rats were deeply anesthetized for transcardial
perfusion (1x phosphate buffered saline and 4% paraf-
ormaldehyde), and blood, liver, fecal boli, and cecal sam-
ples were collected, snap frozen using dry ice and stored at
−80 °C until further analyses. Microglia quantity was
analyzed by immunoﬂuorescent-immunohistochemistry of
the microglial marker ionized calcium-binding adapter
molecule-1 (Iba-1, Wako, 019-19741) on 40 µm coronal
brain sections from the infralimbic and prelimbic PFC. For
method details see Supplementary Methods.
Minocycline tissue extraction and HPLC analyses
A sensitive and speciﬁc reversed-phase high-perfor-
mance liquid chromatographic (HPLC) method was
developed and optimized for detection of minocycline in
liver tissue and fecal boli. The limit of quantitation was
50 ng/ml with an averaged recovery from homogenates of
95%, with a 5–10% intra- and inter-assay coefﬁcient (see
Supplementary Methods).
Determination of plasma beta-hydroxybutyrate levels
Beta-hydroxybutyrate concentrations (3-OH-butyrate;
stimulated by butyrate release) in plasma were determined
with a commercial assay kit (Sigma-Aldrich, Germany).
The enzyme reaction results in a colorimetric product
proportional to the presence of the metabolite 3-OH-
butyrate (see Supplementary Methods).
Luminex® cytokine detection assay
Interferon (IFN)-γ and interleukin (IL)-12p40 con-
centrations were quantiﬁed in plasma using a cytokine
bead immunoassay (Invitrogen/ThermoFisher Scientiﬁc,
Darmstadt, Germany) and the Luminex xMAP 100 system
(Luminex, Austin, TX, USA) according to the manu-
facturer’s protocol (see Supplementary Methods).
Intestinal microbiome analysis by 16S-rDNA
pyrosequencing
The methods used for the isolation of DNA from stool
specimens, quantiﬁcation of 16S-rDNA copies by qPCR,
PCR ampliﬁcation of V3-V6 16S-rDNA variable regions,
454 pyrosequencing (see Supplementary Table S1 for
primer sequences), sequence processing and operational
taxonomic unit (OTU) clustering as well as analysis of
microbial composition and global community structure
are described in the Supplementary Methods.
Statistical analysis
Behavioral data, plasma 3-OH-butyrate, and cytokine
concentrations were analyzed with the software package
SPSS (version 12) using either one-way analysis of var-
iance (ANOVA; factor treatment), two-way ANOVA
(factors trait×treatment) or two-way ANOVA for repe-
ated measures (factors trait×treatment×stimulus) fol-
lowed by a Bonferroni post hoc test for multiple
comparisons when appropriate. For analysis of cytokine
concentrations, a Mann–Whitney U-test was applied (for
detailed statistical analysis see Supplementary Table S2 as
well as ﬁgure descriptions; for detailed group sizes see
Supplementary Table S2). Group sizes were deﬁned by
power analysis and experimental experience. Animals
were excluded from statistical analysis, if the respective
parameter differed more than twice the standard devia-
tion from the group mean. For microbiome data, the
observed OTU numbers, 16S-rDNA copy numbers, and
relative abundances of bacterial taxa were analyzed in R
by ANOVA with a subsequent Tukey’s test. Pairwise
multilevel comparisons of Bray–Curtis distances as
depicted in the PCoA plot were analyzed using the vegan
package in R followed by a Bonferroni correction to adjust
p values. Correlations between bacterial families and
plasma butyrate were calculated using Spearman’s corre-
lation coefﬁcients in GraphPad Prism (version 5). Sig-
niﬁcance was accepted at p ≤ 0.05.
Results
Behavioral effects of minocycline in the SPT, LDB, EPM, and
FST
Male and female HAB and NAB rats were treated with
either minocycline (40 mg/kg), escitalopram or a combi-
nation of both via the drinking water for 22 days, and ﬂuid
intake was monitored daily (see supplementary results
Table S3 and Fig. S1). In the SPT, all rats displayed natural
social preference as indicated by a higher investigation
time of the social versus the non-social stimulus (p <
0.001; Fig. 1b–e). Post hoc analyses revealed that mino-
cycline alone facilitated social approach in male (Fig. 1b)
and female (Fig. 1c) HAB rats (p < 0.05 vs. Veh). In both
the LDB and EPM, the expected anxious phenotype of
HAB rats was visible in both sexes compared to NAB rats
(p < 0.05; Fig. S2). A treatment effect was only seen in
male NAB rats, where escitalopram alone increased the
time in the light box (p < 0.05).
Concomitant with the high anxiety phenotype, male and
female HAB rats displayed reduced struggling and
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Fig. 1 (See legend on next page.)
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increased immobility in the FST compared to NABs (p <
0.001; Fig. 1f–i). Minocycline was the only treatment that
reversed this phenotype, but exclusively in male HAB rats
indicated by decreased immobility and increased strug-
gling (p < 0.05 vs. Veh, Fig. 1f, h). No treatment-induced
changes in locomotion in HAB rats (Fig. S2) and no
inﬂuence of the female cycle on behavior was detectable
(data not shown).
To assess potential sex-dependent differences in effec-
tive doses, 80 mg/kg minocycline was also administered to
male and female HAB rats. Again, minocycline increased
social preference in both sexes (p < 0.001; Fig. S3A, B) and
ameliorated depressive-like behavior in male HAB rats (p
< 0.05; Fig. S3G–J), whereas anxiety-like behavior
remained unchanged (Fig. S3C–F). Hence, in all following
analysis, only samples from the 40mg/kg groups were
analyzed.
Effects of minocycline on microglial numbers in the PFC
and cytokine concentrations in plasma
The effects of minocycline, escitalopram, or the com-
bination on microglial quantity in infralimbic/prelimbic
PFC slices were assessed using Iba-1 as a marker of both
resting and reactive microglia. In male (p < 0.001; Fig. 2a)
and female (p < 0.01; Fig. 2b) HAB rats, overall lower
counts of microglia cells were detected compared to NAB
rats. A treatment effect was seen exclusively in male HAB
rats with post hoc analysis revealing further reduced
microglial numbers after minocycline treatment (p < 0.05;
Fig. 2a). As only male HAB rats responded both beha-
viorally and in microglial numbers to minocycline, all
subsequent analyses, i.e. of peripheral pro-inﬂammatory
cytokine concentrations and microbiome composition,
were performed exclusively in minocycline-treated male
HAB vs. NAB rats. Minocycline reduced IFN-γ levels in
male HAB and NAB rats (p < 0.05; Fig. 3a), whereas IL-12
subunit p40 levels remained unchanged (Fig. 3b).
Distribution of minocycline in liver and fecal boli
Minocycline was detectable in fecal boli suggesting its
signiﬁcant availability in the large intestine, including the
cecum (Table 1). Comparable levels were found in the
liver of both male and female rats irrespective of trait
anxiety. This correlated with liquid (i.e. minocycline)
intake on the last treatment day (data not shown).
Intestinal microbial composition
After 16S-rDNA-based high-throughput sequencing,
analysis revealed comparable total bacterial 16S-rDNA
copy numbers and microbial richness, represented by
OTU counts, in HAB and NAB rats, which was reduced
by minocycline in both lines (p < 0.01; Fig. 4a, b). The
overall composition of cecal microbiota, as assessed by
principal coordinates analysis of Bray–Curtis distances
(beta-diversity), revealed marked differences between
HAB and NAB rats shown by four distinct clusters cor-
responding to the two treatment conditions (p= 0.012;
Fig. 4c). This analysis clearly shows a strong perturbation
of the gut microbiota as a response to minocycline
application in both rat lines and diminished differences
between HABs and NABs following treatment.
In detail, striking differences between HAB and NAB
rats were identiﬁed regarding the highly prevalent Lach-
nospiraceae family of the Clostridiales order (p < 0.05;
Fig. 4d). Minocycline treatment elevated the lower fre-
quency in HABs to the level of NABs that — in terms of
this family — were not affected by treatment. Further, a
relative increase in the abundance of the Clostridiales
Family XIII in both lines was observed after minocycline
(p < 0.01; Fig. 4e). Interestingly, many Lachnospiraceae
members as well as a number of Clostridiales Family XIII
strains have been implicated in the production of butyrate
that exerts important pleiotropic functions in the intest-
inal tract and beyond49. Consistently, we found sig-
niﬁcantly augmented levels of 3-OH-butyrate after
minocycline treatment in both lines that was even higher in
HAB compared to NAB rats (p < 0.05; Fig. 4f). Spearman’s
rank analysis disclosed positive correlations between 3-OH-
butyrate levels and abundance of the two mentioned
Clostridiales families in individual HAB rats corroborating
an important contribution of the respective bacteria to
systemic butyrate availability (p < 0.001; Fig. 4g, i). In NAB
rats, minocycline-induced augmentation of the Family XIII
population, but not of Lachnospiraceae, positively
(see ﬁgure on previous page)
Fig. 1 Experimental design and behavioral outcome after treatment of male and female NAB and HAB rats with either vehicle (Veh),
minocycline (Min), escitalopram (Esc), or a combination of both (Min+Esc) for 22 days. a After 15 days of treatment, social preference behavior
was tested in the social preference test (SPT), followed by evaluation of anxiety-like behavior in the light–dark box (LDB; day 17) and the elevated
plus-maze (EPM; day 19), and of depressive-like behavior in the pre-swim (day 21) and forced swim test (FST; day 22). Social preference is reﬂected by
longer investigation of the social (+) versus the non-social (−) stimulus in the SPT, whereas depressive-like behavior is reﬂected as total score spent
struggling and immobile during the FST. All male (b, d) and female (c, e) HAB and NAB rats showed natural social preference (signiﬁcance not
indicated), which is facilitated in male and female HAB rats by Min. A depressive-like phenotype was observed in all male (f, h) and female (g, i) HAB
rats in the FST compared to NAB rats except male HAB rats that were treated with Min (f, h). Data represents mean+ s.e.m., *p < 0.05 vs.
corresponding Veh group, +++p < 0.001 vs. NAB; SPT: one-way ANOVA for repeated measures; FST: two-way ANOVA, followed by a Bonferroni post
hoc test
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Fig. 2 Number of Iba-1 positive (Iba+) microglia cells in the prefrontal cortex (PFC; prelimbic/infralimbic) of male and female NAB and
HAB rats on day 22 of treatment with either vehicle (Veh), minocycline (Min), escitalopram (Esc), or a combination of both (Min+Esc). Both
HAB males (a) and females (b) showed overall reduced microglial numbers in the PFC compared to NAB rats independent of treatment. Min alone
further reduced microglial numbers exclusively in male HAB rats (a). Representative microphotographs of the analyzed PFC with Iba+ microglia
(green) and DAPI+ (blue) staining (c, d). Data represents mean+ s.e.m., *p < 0.05 vs. corresponding Veh group; ++p < 0.01, +++p < 0.001 vs. NAB;
two-way ANOVA, followed by a Bonferroni post hoc test; n= 6. Scale bar: 50 µm
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correlated with 3-OH-butyrate levels (p < 0.001; Fig. 4h, j),
which presumably accounted for the moderate increase in
3-OH-butyrate concentrations of NABs.
Discussion
In the present study, we conﬁrm the antidepressant
effect of minocycline and reveal that chronic minocycline
treatment reduces depressive-, but not anxiety-like,
behavior and affects the gut–brain axis in a sex- and trait
anxiety-dependent manner. These ﬁndings extend pre-
vious reports of antidepressant actions of minocy-
cline18,20,25,26,28,50 to male rats with high levels of innate
anxiety- and depressive-like behavior. In addition, chronic
minocycline facilitated social preference behavior in HAB
males and females as indicated in previous studies25,51,52.
However, as HAB rats generally do not show impairments
in social interaction, the elevated social preference rather
seems to reﬂect an alleviation of depressive-like beha-
vior36,53 than an improvement in social approach per se.
Interestingly, we could not replicate the proposed
anxiolytic-like effect of minocycline17,50 either in HAB or
NAB rats. Thus, it appears that anxiety-like behavior in
HAB rats is manifested via a mechanism independent of
the inﬂammatory system or any other target of minocy-
cline33,54. Importantly, the antidepressant effect of mino-
cycline was not observed in female HAB rats. Similarly,
minocycline was able to abolish inﬂammatory neuro-
pathic pain55 and improved morphine-induced analge-
sia56 only in male mice, proposing a sex-speciﬁcity of its
actions. Of note, we carefully considered an inﬂuence of
repeated testing57,58 on the behavioral effects of minocy-
cline and, accordingly, the least stressful test (SPT) was
performed ﬁrst, and the most stressful test (FST) last, with
a full day of rest between two tests to avoid stress- or
experience-induced bias.
Chronic escitalopram59 or citalopram60 treatment has
been described to ameliorate chronic stress-induced
depressive-like behavior in both rats and mice, and cita-
lopram and paroxetine given over 8 weeks have also been
proven to be effective in HAB males34,35. In the present
study we could only reproduce the anxiolytic effect of
escitalopram in male NAB rats in the LDB, but not in
HAB or female rats, probably due to the short treatment
time. Importantly, these results support a sex difference in
treatment strategies for MDD and validate the HAB
breeding line as a model for innate treatment-resistant
depressive-like behavior with minocycline as a potential
treatment.
Clinical studies provide growing evidence for an
increased efﬁcacy of adjunctive treatment in MDD5. Fit-
tingly, minocycline treatment, in combination with sev-
eral conventional antidepressants like SSRIs or
antipsychotics, improved MDD symptoms19–21. However,
a study in depressed patients revealed that administration
of citalopram in combination with a non-steroidal anti-
inﬂammatory drug inhibited remission61. In keeping, in
the present study 3-week treatment with minocycline
Fig. 3 Cytokine concentration in plasma samples of male HAB and NAB rats on day 22 of vehicle (Veh) or minocycline (Min) treatment.
Interferon (IFN)-γ and interleukin (IL)-12p40 levels were measured by a Luminex® bead immunoassay. Min reduced IFN-γ concentrations in both HAB
and NAB rats (a), while IL-12p40 levels were not affected (b). Data represents mean + s.e.m., *p < 0.05 vs. corresponding Veh group; Mann–Whitney
U-test
Table 1 Minocycline concentration in liver and fecal boli
of male and female rats
Sex Treatment Fecal boli [µg/mg] Liver [µg/mg]
♂ VEH 0 ± 0 0 ± 0
Minocycline 1.26 ± 0.11 1.05 ± 0.08
♀ VEH n.a. 0 ± 0
Minocycline n.a. 1.12 ± 0.10
Data depicts mean concentration values ± s.e.m. of minocycline in tissue/stool of
pooled HAB and NAB rats per sex; n (liver) = 13 (♀) or 36 (♂), n (fecal boli) = 6;
n.a. = not assessed
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Fig. 4 (See legend on next page.)
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together with escitalopram abolished the antidepressant
effect of minocycline. In agreement with our results,
minocycline in combination with the SSRI ﬂuoxetine, but
not the tricyclic desipramine, prevented the anti-
depressant effects of minocycline in rats23,24. Together,
these ﬁndings strongly suggest that minocycline speciﬁ-
cally counteracts a mechanism responsible for the
antidepressant-like effect of SSRIs. Though minocycline
interferes with the effectiveness of escitalopram in this
case, it does not necessarily target the monoaminergic
mode of action, but might target substance-speciﬁc sec-
ondary mechanisms or elicit local pharmacokinetic
interactions.
Minocycline has been repeatedly demonstrated to
inhibit microglial activity and proliferation accompanying
its effects on behavior16,17,26,28,43,50,62,63 and - as an anti-
biotic - to modulate the gut microbial composition18.
Neuroinﬂammation and increased microglial activation
have been associated with MDD8,27,43,64,65. However, a
dynamic and bi-directional alteration in microglial status
has recently been hypothesized to underlie depressive-like
behavior, as microglial numbers were found to be initially
elevated followed by their decline in the hippocampus and
PFC of chronically stressed rodents that displayed
depressive-like behavior51. The lower microglial density in
the PFC of HAB rats is likely due to their permanent
stress state, as shown by elevated trait anxiety and a
hyper-reactive HPA axis66. Interestingly, administration
of minocycline further reduced microglial numbers, spe-
ciﬁcally in male HAB rats, which paralleled the
antidepressant-like behavioral effect. Similar to a reduc-
tion in microglia, acute inhibition of the infralimbic cortex
in male HAB rats led to an antidepressant-like pheno-
type39, indicating the PFC to be involved in depressive-
like behavior in male HAB rats. Minocycline has been
shown to inhibit microglial proliferation17,67 and, in view
of a constant rate of microglial apoptosis68, should
therefore lead to a further reduced microglial density in
male HAB rats. Although the underlying mechanisms of
the dynamic interplay between proliferation and apoptosis
need to be explored in more detail, our results point
towards an impaired microglial homeostasis and func-
tioning as an underlying mechanism for the depressive-
like behavior in HAB rats, and further support our
breeding line as a model for inﬂammation-associated
depressive-like behavior. Of note, the reduction in
microglial numbers by minocycline was abolished, when
given in combination with escitalopram.
The microbiome-gut–brain axis has been shown to
modulate microglia proliferation and maturation. For
example, phenotypical abnormalities of microglia found
in germ-free mice were reversed by a microbiota-derived
short-chain fatty acid mixture containing butyrate12. Gut
microbiota dysbiosis, in turn, can result in neuroin-
ﬂammation by chronic activation of microglia in the
CNS69, potentially contributing to the behavioral pheno-
type in HAB rats. Supporting the link between the
microbiome and emotional behavior6,9,70, HAB and NAB
rats originating from the same breeding facility show -
despite comparable total bacterial numbers in their cecal
contents - profound differences in global gut microbiota
composition, reﬂecting the robust behavioral differences
between the two lines. As expected, 3 weeks of minocy-
cline treatment reduced bacterial richness similarly in
both groups resulting in still persisting, but diminished
group differences. This suggests a partial equalization of
the microbiota between both lines that might contribute
to the observed antidepressant-like effect of minocycline
in HAB rats. Interestingly, in patients suffering from
MDD, an altered microbial composition was observed
that induced similar symptoms in rats upon
transplantation71,72.
Importantly, detailed microbiome comparison between
HAB and NAB rats revealed decreased relative abundance
of the Lachnospiraceae family in HABs, which expanded
after minocycline treatment. Similar dynamic changes in
Lachnospiraceae were found in a stress model of
depression18. We further show that minocycline elevated
(see ﬁgure on previous page)
Fig. 4 Cecal microbiota composition and plasma 3-OH-butyrate levels after 22 days of vehicle (Veh) or minocycline (Min) treatment. HAB
and NAB rats showed comparable levels of 16S-rDNA copy numbers that were similarly diminished by Min (a) and comparable bacterial richness of
the microbiome between both lines, as indicated by operational taxonomic units (OTU) numbers, that were decreased by Min (b). Beta-diversity of
bacterial communities prevalent in cecal contents, as illustrated by principal coordinates analysis (PCoA) of Bray–Curtis distances with the ﬁrst two
coordinates plotted, showed four distinct clusters corresponding to all treatment groups (c). Connected symbols represent data from individual rats,
color-coded by the indicated groups. Regarding Clostridiales families, HAB rats show a reduced abundance of Lachnospiraceae that was increased to
NAB level by Min (d). Further, both lines show comparable levels of Clostridiales Family XIII with increased abundance after Min treatment (e). These
changes were accompanied by increased plasma 3-OH-butyrate levels (f) with a higher increase in HAB compared to NAB rats. In HAB rats, plasma 3-
OH-butyrate levels correlated positively with both Clostridiales families (g, i) whereas in NAB rats, a positive correlation was only observed with Family
XIII (h, j; open symbols indicate Veh-treated, colored symbols Min-treated rats) as determined by Spearman’s correlation. Boxes in a, b, d, and e
represent interquartile range with horizontal lines indicating the median of values, outliers indicate values more than 1.5 times of upper/lower
quartile, and whiskers show minimum and maximum of remaining values. Bars represent mean+ s.e.m; two-way ANOVA was used for statistical
analysis
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relative Clostridiales Family XIII levels in both HAB and
NAB rats. Both Lachnospiraceae and Clostridiales Family
XIII accommodate a large part of butyrate-producing
bacterial genera, reﬂected by increased plasma 3-OH-
butyrate levels especially in HAB, but also in NAB rats,
after minocycline. In support, a positive correlation
between the abundance of Lachnospiraceae, as well as the
Clostridiales Family XIII, with 3-OH-butyrate was found
in male HAB rats. In contrast, in male NABs a positive
correlation was only found with Clostridiales Family XIII.
Both butyrate and 3-OH-butyrate have been proposed as
anti-inﬂammatory agents that execute their effects via
inhibition of peripheral T cell activity73 and microglia
activation74, and even via inducing microglial apoptosis75.
In line, minocycline decreased the level of the pro-
inﬂammatory cytokine IFN-γ, produced by IL-12-induced
and activated T-helper type 1 cells76, in both HAB and
NAB males. Plasma levels of IL-12p40 appeared to be
higher in HAB rats and were reduced by minocycline to
NAB levels, supporting a regulatory role of minocycline
and butyrate on peripheral T cells73,77 independent of the
central immune system that might contribute to the
antidepressant effect of minocycline. Although a role of
butyrate in the regulation of the central immune system
remains to be studied, our results suggest that butyrate-
mediated microglial apoptosis75 might contribute to the
observed reduction in microglial density in the PFC of
male HAB rats. Furthermore, butyrate has been shown to
exert antidepressant-like effects in mice78,79 and rats80.
These ﬁndings point towards an important role of
bacteria-produced butyrate as a mediator of behavioral
and microglial alterations in minocycline-treated HAB
rats. Thus, our results support the hypothesis of an
inﬂuence of the gut microbiome on anxiety- and
depressive-like behavior in our rodent model of anxiety
and depression.
In summary, we show that the depressive- and anxiety-
like phenotype of HAB rats is accompanied by reduced
microglial numbers in the infralimbic/prelimbic PFC and
a distinct shift of the gut-bacterial composition. This
emphasizes that HAB rats are a valid model for
inﬂammation-associated depressive-like behavior and
points towards a complex interplay between microbiota/
microbial metabolites and the immune system, as pro-
posed by the concept of the microbiota-gut–brain axis.
In the course of clinical application, the present results
indicate that promoting an anti-inﬂammatory state by
control of microglial activation and/or modulation of the
gut microbiome and metabolome, as shown after pro-
longed minocycline treatment, offers promising potential
as a therapeutic strategy in treatment-resistant MDD. The
present study was designed to detect an early response
(3 weeks) to minocycline and did not mimic a clinical
antidepressant treatment. Thus, a longer treatment
duration might reveal different effects. Nevertheless,
caution is needed when considering minocycline as an
augmentation strategy of SSRIs like escitalopram, espe-
cially in the absence of a pro-inﬂammatory proﬁle, which
may explain some of the recent high-proﬁle clinical fail-
ures of minocycline.
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